GenEditBio Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 7

GenEditBio General Information

Description

Developer of gene editing drugs designed to meet unmet medical needs. The company focuses on the research and development of innovative gene editing drugs and is rapidly advancing in vivo gene editing tools and related delivery systems, providing clients with curative gene editing-based solutions for genetic diseases.

Contact Information

Website
www.geneditbio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 4th Floor, Building 29, yard 18
  • Kechuang 13th Street, Beijing Economic and Technological Development Zone
  • Beijing, 100176
  • China
+86 010
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 4th Floor, Building 29, yard 18
  • Kechuang 13th Street, Beijing Economic and Technological Development Zone
  • Beijing, 100176
  • China
+86 010

GenEditBio Timeline

2022202320242025
Date FoundedFinancing Round

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GenEditBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC 12-Oct-2024 Completed Pre-Clinical Trials
3. Early Stage VC 03-Apr-2024 Completed Pre-Clinical Trials
2. Early Stage VC 01-Apr-2022 $25M $34M Completed Pre-Clinical Trials
1. Early Stage VC 02-Nov-2021 $9M $9M Completed Startup
To view GenEditBio’s complete valuation and funding history, request access »

GenEditBio Patents

  • 4

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 4

    Pending

  • Expiring in next 12 mo

GenEditBio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4490293-A1 Modified crispr-based gene editing system and methods of use Pending 09-Mar-2022
US-20240191295-A1 Methods of enriching targeted nucleic acid, identifying off-target and evaluating gene editing efficiency Pending 16-May-2021
EP-4352257-A2 Methods of enriching targeted nucleic acid, identifying off-target and evaluating gene editing efficiency Pending 16-May-2021
EP-4352257-A4 Methods of enriching targeted nucleic acid, identifying off-target and evaluating gene editing efficiency Pending 16-May-2021 C12Q1/6876

GenEditBio Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Gobi Partners Venture Capital Minority
Center Laboratories Accelerator/Incubator Minority
HKSTP Ventures Corporate Venture Capital Minority
Innovation and Technology Fund Government Minority
Lumosa Therapeutics Company Corporation Minority
You’re viewing 5 of 7 investors. Get the full list »

Ready to get started?

Request a free trial

GenEditBio FAQs

  • When was GenEditBio founded?

    GenEditBio was founded in 2021.

  • Where is GenEditBio headquartered?

    GenEditBio is headquartered in Beijing, China.

  • What industry is GenEditBio in?

    GenEditBio’s primary industry is Drug Discovery.

  • Is GenEditBio a private or public company?

    GenEditBio is a Private company.

  • What is GenEditBio’s current revenue?

    The current revenue for GenEditBio is .

  • How much funding has GenEditBio raised over time?

    GenEditBio has raised $124M.

  • Who are GenEditBio’s investors?

    Gobi Partners, Center Laboratories, HKSTP Ventures, Innovation and Technology Fund, and Lumosa Therapeutics Company are 5 of 7 investors who have invested in GenEditBio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »